Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Patients with primary systemic amyloidosis will be treated with CC-5013 (lenalidomide;
Revlimid) as a single agent for 3 months. If their disease worsens or does not improve during
that time frame dexamethasone will be added to the treatment program.